EC Number   |
Application |
Reference |
|---|
   3.4.13.20 | analysis |
a validated method for measuring serum carnosinase activity in serum and heparin plasma |
647118 |
| 3.4.13.20 | medicine |
CNDP1 secretion is significantly higher in cells expressing variants with more than five leucines in the signal peptide of the protein. This explains why individuals homozygous for the 5L allele have low serum carnosinase activity and why diabetic patients homozygous for CNDP1 5L are protected against diabetic nephropathy |
683393 |
| 3.4.13.20 | medicine |
diabetic patients with the CDDP1 Mannheim variant(shortest allelic form) are less susceptible for nephropathy |
668378 |
| 3.4.13.20 | medicine |
liver-specific expression of enzyme in db/db mice, a model of type 2 diabetes. Transgenic mice shows reduced body weight as a result of glucosuria. Fasting plasma glucose as well as hemoglobin A1C levels rise earlier and remain higher throughout their life than in control animals. Serum fasting insulin levels are low and elevated by L-carnosine feeding. Insulin resistance and insulin secretion are not significantly affected by L-carnosine serum levels. Instead, a significant correlation of L-carnosine levels with beta-cell mass is observed |
683394 |
| 3.4.13.20 | medicine |
monoclonal antibody RYSK173 recognizes a sequence within the transition metal binding site of CNDP1. The CN-1 RYSK173 proportion appears overall increased in end-stage renal disease patients, yet it decreases during hemodialysis possibly as a consequence of a relative increase in transition metal bound enzyme |
755112 |
| 3.4.13.20 | medicine |
no difference in allele or genotype frequency between centenarians and their control group, or between vascular patiens and their control group. Detection of a rare 8-leucine allele, of a rare duplication, p.L13_V15dup, and a frameshift deletion, L17fsX20 |
683849 |
| 3.4.13.20 | medicine |
serum CNDP1 concentrations associate with CNDP1 genotype and renal function in patients with type 2 diabetes mellitus. CNDP1 (CTG)5 homozygous patients with type 2 diabetes mellitus with diabetic nephropathy have significantly lower CNDP1 concentrations and activity than those without nephropathy. Lower serum CNDP1 concentrations correlate with impaired renal function and to a lesser extend with the CNDP1 genotype |
752460 |
| 3.4.13.20 | medicine |
study on carnosinase activity in patients with Alzheimer's disease and with mixed dementia. Enzyme activity levels in the mixed disease group are significantly lower than the Alzheimer's disease group and the mixed disease group demonstrates a significant trend with carnosidase activity decreasing with duration of disease. Both Alzheimer and mixed disease patients on any demetia medication have higher carnosinase activity compared to those not taking a dementia medication, and enzyme activity is higher in patients who regurlarly exercise compared to those who do not exercise regurlarly |
683306 |
| 3.4.13.20 | medicine |
the renoprotective effect of L-carnosine on ischemic acute renal failure is induced by its conversion to L-histidine and L-histamine and is mediated through the activation of histamine H3 receptors in the central nervous system |
683812 |
| 3.4.13.20 | synthesis |
attachment of a beta-amino acid to the N-terminus of a natural alpha-peptide. N-terminal beta-amino acid residues may be considered as protective groups against proteolytic enzymes in vitro and in vivo |
-, 708080 |
